DE60327363D1 - Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen - Google Patents

Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen

Info

Publication number
DE60327363D1
DE60327363D1 DE60327363T DE60327363T DE60327363D1 DE 60327363 D1 DE60327363 D1 DE 60327363D1 DE 60327363 T DE60327363 T DE 60327363T DE 60327363 T DE60327363 T DE 60327363T DE 60327363 D1 DE60327363 D1 DE 60327363D1
Authority
DE
Germany
Prior art keywords
tamoxifes
hydroxy
density
reducing
breast tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327363T
Other languages
English (en)
Inventor
Jay Bua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Besins International SAS
Original Assignee
Laboratoires Besins International SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Besins International SAS filed Critical Laboratoires Besins International SAS
Application granted granted Critical
Publication of DE60327363D1 publication Critical patent/DE60327363D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
DE60327363T 2002-12-18 2003-12-15 Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen Expired - Lifetime DE60327363D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43395802P 2002-12-18 2002-12-18
PCT/EP2003/015030 WO2004054558A2 (en) 2002-12-18 2003-12-15 Reduction of breast density with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
DE60327363D1 true DE60327363D1 (de) 2009-06-04

Family

ID=32595254

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60327363T Expired - Lifetime DE60327363D1 (de) 2002-12-18 2003-12-15 Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen

Country Status (6)

Country Link
US (1) US7485623B2 (de)
EP (3) EP1572171B1 (de)
JP (2) JP4684655B2 (de)
AU (1) AU2003296757A1 (de)
DE (1) DE60327363D1 (de)
WO (1) WO2004054558A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471400A1 (en) * 2001-12-20 2003-07-03 Femmepharma, Inc. Vaginal delivery of drugs
JP4938237B2 (ja) * 2002-12-18 2012-05-23 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房痛の治療
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
CA2511995C (en) * 2003-01-02 2012-03-13 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
EP1952810B1 (de) * 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Behandlung von Brustkrebs mit 4-Hydroxy-Tamoxifen
WO2004110420A1 (en) 2003-06-09 2004-12-23 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (de) * 2004-03-22 2005-09-28 Laboratoires Besins International 4-Hydroxytamoxifen zur Behandlung von benignen Brusterkrankungen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (de) * 2004-03-22 2005-09-28 Laboratoires Besins International Stabile Zusammensetzungen enthaltend 4-hydroxy Tamoxifen
ATE391499T1 (de) * 2004-03-22 2008-04-15 Besins Int Lab 4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen
EP1647271A1 (de) * 2004-10-14 2006-04-19 Laboratoires Besins International Gelzubereitung enthaltend 4-Hydroxy tamoxifen.
EP1799201B1 (de) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxytamoxifengel-formulierungen
GB0602739D0 (en) * 2006-02-10 2006-03-22 Ccbr As Breast tissue density measure
WO2008083158A2 (en) * 2006-12-26 2008-07-10 Femmepharma Holding Company, Inc. Topical administration of danazol
EP2224909A1 (de) * 2007-11-22 2010-09-08 Novo Nordisk Health Care AG Stabilisierung von flüssigkeitsformulierten faktor-vii(a)-polypeptiden durch aldehydhaltige verbindungen
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
WO2015175561A1 (en) * 2014-05-12 2015-11-19 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
CA3032153A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
AU2018329202B2 (en) 2017-09-11 2022-10-27 Atossa Therapeutics, Inc. Methods for making and using endoxifen
WO2023026139A1 (en) * 2021-08-23 2023-03-02 Singh Divya Dhananjay Pharmaceutical composition comprising 4- hydroxytamoxifen for the treatment of mastalgia

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
DE3781546D1 (de) 1987-04-21 1992-10-08 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-beta-dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en.
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US5002938A (en) * 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
TW218849B (de) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
JPH0679002A (ja) * 1993-12-14 1994-03-22 Hisamitsu Pharmaceut Co Inc 経皮投与用パッチシステム
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
DE4434165A1 (de) * 1994-09-24 1996-03-28 Cassella Ag Haarfärbemittel
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6013270A (en) 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ES2330188T3 (es) 2001-12-07 2009-12-07 Besins Manufacturing Belgium Composicion farmaceutica en forma de gel o de solucion a base de dihidrotestoterona, su procedimiento de preparacion y sus utilizaciones.
JP4938237B2 (ja) 2002-12-18 2012-05-23 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房痛の治療
EP1952810B1 (de) 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Behandlung von Brustkrebs mit 4-Hydroxy-Tamoxifen
WO2004110420A1 (en) 2003-06-09 2004-12-23 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (de) 2004-03-22 2005-09-28 Laboratoires Besins International Stabile Zusammensetzungen enthaltend 4-hydroxy Tamoxifen
EP1647271A1 (de) 2004-10-14 2006-04-19 Laboratoires Besins International Gelzubereitung enthaltend 4-Hydroxy tamoxifen.

Also Published As

Publication number Publication date
AU2003296757A8 (en) 2004-07-09
WO2004054558A3 (en) 2004-10-28
WO2004054558A2 (en) 2004-07-01
US20040138314A1 (en) 2004-07-15
AU2003296757A1 (en) 2004-07-09
EP1952809B1 (de) 2017-08-02
EP1952809A2 (de) 2008-08-06
JP4684655B2 (ja) 2011-05-18
EP1572171B1 (de) 2009-04-22
US7485623B2 (en) 2009-02-03
EP2050443B1 (de) 2017-05-24
JP2006514645A (ja) 2006-05-11
EP1952809A3 (de) 2012-06-20
JP2011052020A (ja) 2011-03-17
EP1572171A2 (de) 2005-09-14
EP2050443A1 (de) 2009-04-22

Similar Documents

Publication Publication Date Title
DE60327363D1 (de) Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
DE60319837D1 (de) Neue benzodioxole
DE60318769D1 (de) Maskenüberzug
NO20055657D0 (no) Nye bioisostaererav aktinonin
DE60334091D1 (de) Flammhemmendes mischgewebe
DE50309688D1 (de) Substituierte 2-phenyl-3(2h)-pyridazinone
FI20031750A0 (fi) Mammografialaite
FR2863747B1 (fr) Fiabilisation des cartes dual interface par grille continue
ATE394140T1 (de) Verwendung neuer etonogestrelester
DE10394301D2 (de) Ultraschallreaktor
NO20044140D0 (no) New Composition
HK1077512A1 (en) Reduction of breast density with 4-hydroxy tamoxifen
FR2881942B1 (fr) Materiel d'osteosynthese
FR2887433B1 (fr) Plaque d'osteotomie tibiale d'addition
FR2838959B1 (fr) Bassin medical
UA12148S (uk) Крісло м'яке
UA12146S (uk) Крісло м'яке
UA12150S (uk) Крісло м'яке
UA12147S (uk) Крісло м'яке
ITGE20050028A1 (it) Monopattino d'acqua.
EE00378U1 (et) Ujumislesta laba
SE0203755D0 (sv) Malmetoder
SE0201678D0 (sv) Malmetoder
ITMI20051145A1 (it) "procedimento per la preparazione di fosfenitoina"
TH134450B (th) เครื่องทำไอหอมระเหยด้วยอัลตราโซนิกส์

Legal Events

Date Code Title Description
8364 No opposition during term of opposition